Aggarwal, R., Bhatt, D. L., Szarek, M., Leiter, L. A., Cannon, C. P., Lopes, R. D., … Steg, P. G. (2024). Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial. Eur J Heart Fail, 26(4), 1093–1095. https://doi.org/10.1002/ejhf.3240

Aggarwal, Rahul, Deepak L. Bhatt, Michael Szarek, Lawrence A. Leiter, Christopher P. Cannon, Renato D. Lopes, Michael J. Davies, Phillip Banks, Bertram Pitt, and Ph Gabriel Steg. “Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.” Eur J Heart Fail 26, no. 4 (April 2024): 1093–95. https://doi.org/10.1002/ejhf.3240.

Aggarwal R, Bhatt DL, Szarek M, Leiter LA, Cannon CP, Lopes RD, et al. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial. Eur J Heart Fail. 2024 Apr;26(4):1093–5.

Aggarwal, Rahul, et al. “Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.” Eur J Heart Fail, vol. 26, no. 4, Apr. 2024, pp. 1093–95. Pubmed, doi:10.1002/ejhf.3240.

Aggarwal R, Bhatt DL, Szarek M, Leiter LA, Cannon CP, Lopes RD, Davies MJ, Banks P, Pitt B, Steg PG. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial. Eur J Heart Fail. 2024 Apr;26(4):1093–1095.